AGITG Trial News

The AGITG currently has six studies open to recruitment and ten studies in follow up. Please find following, a table indicating the trials which are still recruiting, and where the recruited patients numbers measure up against the trial target. Recruited Target ACTICCA-1- gallbladder carcinoma 0 50 ALT-GIST- GI Stromal Tumour 20 240 … Read More

August 9, 2016

NSW awards outstanding cancer researcher

Professor John Simes, AGITG Director and Director of the National Health and Medical Research Centre (NHMRC) has been awarded the NSW Premier’s Award for Outstanding Cancer Research. This is an annual award and the leading NSW awards program that celebrates excellence and innovation in cancer research. Professor John Simes is … Read More

August 8, 2016

AGITG @ ESMO 2016

This year the AGITG will be well represented at the European Society For Medical Oncology, (ESMO) the leading European professional organisation for medical oncology. In 2016 the ESMO Congress conference will be held in Denmark, Copenhagen from 7-11 October. Abstracts will include: the DOCTOR clinical trial; the MAX study; CO.17-CO.20; and CO.23. … Read More

August 4, 2016

Minimising missing PRO data

Patient-reported outcomes provide information about the impact of disease and treatment on the patient, and PROs can be interpreted in the context of other trial outcomes to provide a comprehensive assessment of treatment benefits and harms. PRO studies often suffer from missing data, which, if not handled appropriately, can cause … Read More

August 4, 2016

InterAACT now open at several sites

InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable advanced or metastatic anal cancer. By comparing two well-known and widely used combination chemotherapies (cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel), we aim to demonstrate which one is more effective and … Read More

August 2, 2016

ACTICCA-1 open to recruitment

Recently, ACTICCA-1 was opened for recruitment at the Bankstown-Lidcombe Hospital in NSW. This is a multicentre, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation versus observation alone in patients after curative intent resection of cholangiocarcinoma (CCA) and muscle invasive gallbladder … Read More

August 2, 2016

2016 Pancreas Cancer Research Workshop

Call for Submissions: AGITG – APC Pancreas Cancer Research Workshop The AGITG and the Australasian Pancreatic Club (APC) are again hosting a Pancreas Cancer Research Workshop to be held on 13 September in conjunction with the AGITG Annual Scientific Meeting.  Now is the time to develop a concept to present. When: … Read More

July 19, 2016

TACTIC Study published

The AGITG TACTIC study, a Phase II trial of gemcitabine, cisplatin and panitumumab in biliary tract cancer was recently published in the Cancer Chemotherapy and Pharmacology Journal. The aim of the study was to determine the activity and safety gemcitabine, cisplatin and panitumumab in patients with K-ras wild-type locally advanced, … Read More

July 4, 2016

INTEGRATE results published in JCO

The manuscript “Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): a Multinational Placebo- Controlled Phase II Trial” was recently published in the Journal of Clinical Oncology. To read the full article click here. INTEGRATE was a randomised phase II double-blind placebo-controlled study of regorafenib in refractory Advanced Oesophago-Gastric Cancer. … Read More

June 23, 2016

Pancreatic cancer surgical guidelines published

New surgery guidelines have been developed by a team of leading Australian pancreatic cancer experts, who hope this detail will be a major step forward to improved survival rates over the next five years. A report, published today in the Medical Journal of Australia, notes pancreatic cancer is fast becoming … Read More

June 20, 2016